Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health (RAP) agrees to a 12-month extension to its initial one-year commercial licence agreement with Medgate
- The agreement is to use ResApp’s smartphone-based acute respiratory diagnostic test ResAppDx on Medgate’s telehealth platform
- Additionally, Medgate plans to expand the use of ResAppDx across additional patient journeys in its telemedicine services and will expand use into Germany in 2023
- Shares in ResApp are up 3.85 per cent to trade at 13.5 cents at 10:34 am AEST
ResApp Health (RAP) has agreed to a 12-month extension to its initial one-year commercial licence agreement with Medgate.
The agreement is to use ResApp’s smartphone-based acute respiratory diagnostic test ResAppDx on Medgate’s telehealth platform.
The company’s acute respiratory diagnostic test ResAppDx uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone’s inbuilt microphone.
ResApp CEO and Managing Director Dr Tony Keating called Medgate a long-standing, global leader in telehealth.
“It’s pleasing to see that Medgate extending the use of ResAppDx to additional patient journeys for the benefit of more patients and clinicians.
“We believe this is further strong endorsement of the value of ResAppDx to patients, clinicians and telehealth providers.”
Additionally, Medgate plans to expand the use of ResAppDx across additional patient journeys in its telemedicine services and will expand use into Germany in 2023.
Medgate CEO Dr Andy Fischer added that the company has built further evidence of the benefits of ResAppDx to its clinicians and patients.
“We look forward to expanding our use of ResAppDx to further realise these benefits for
our patients.
“Our intention is to be the most innovative leader in the global telehealth market and the adoption of ResApp’s AI plays an important role in helping us to achieve this by transforming the patient journey.”
ResAppDx is CE marked in Europe and TGA approved for Australian Register of Therapeutic Goods (ARTG) listing in Australia.
Shares in ResApp were up 3.85 per cent to trade at 13.5 cents at 10:34 am AEST.
